China’s Asymchem Laboratories has agreed to take over the operation of a Pfizer UK manufacturing facility in Sandwich, Kent, safeguarding dozens of jobs.
Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).